Alternative to Trimo-San for Pessary Maintenance
For pessary maintenance, use low-dose vaginal estrogen cream (such as conjugated equine estrogen 0.3 mg or estradiol cream) applied twice weekly, or alternatively, vaginal moisturizers (polycarbophil-based or hyaluronic acid-based) applied at least twice weekly. 1
Understanding the Context
Trimo-San was a non-hormonal acidifying vaginal gel designed to maintain normal vaginal pH in pessary wearers 2. Since it's no longer available in your formulary, you need alternatives that address the same underlying issue: preventing vaginal atrophy and maintaining tissue health in women using pessaries long-term.
Recommended Approach
First-Line: Low-Dose Vaginal Estrogen
Low-dose vaginal estrogen is the most effective option and should be your primary recommendation for most pessary users experiencing or at risk for vaginal atrophy 1, 3. The evidence strongly supports this:
- Vaginal estradiol 10-µg tablets: Apply daily for 2 weeks, then twice weekly maintenance. This provides the lowest effective dose with minimal systemic absorption 1
- Conjugated equine estrogen (CEE) 0.3 mg cream: Apply twice weekly. This intermediate-dose option offers flexibility and treats from introitus to apex 1
- Low-dose vaginal estradiol ring: Changed every 3 months, though may be expelled in women post-hysterectomy 1
The guideline evidence demonstrates that low-dose vaginal estrogen improves symptoms within 2-3 weeks and maintains effectiveness for at least 1 year 1. Importantly, serum estradiol levels remain within normal postmenopausal range, minimizing systemic risks 1, 3.
Second-Line: Non-Hormonal Options
If the patient cannot or will not use estrogen:
Vaginal moisturizers (polycarbophil-based like Replens, or hyaluronic acid-based preparations) applied at least twice weekly 1. For pessary users specifically, consider increasing frequency to 3-5 times per week as recommended for cancer survivors 4.
Important caveat: These are less effective than vaginal estrogen and may not adequately prevent the tissue breakdown that can occur with chronic pessary use 1.
Third-Line: Newer Agents
- Vaginal DHEA (prasterone 6.5 mg): Insert nightly. Particularly useful for patients on aromatase inhibitors or with breast cancer history 4, 3
- Ospemifene 60 mg oral daily: Only for postmenopausal women without breast cancer history. Has boxed warning for endometrial stimulation and VTE risk 3
Clinical Decision Algorithm
No contraindications to estrogen → Low-dose vaginal estrogen (cream or tablet, twice weekly after initial daily dosing)
Estrogen contraindicated (hormone-sensitive breast cancer on active treatment) → Vaginal moisturizers 3-5x/week, consider DHEA after discussion with oncologist 4
Patient preference for non-hormonal → Vaginal moisturizers at least twice weekly, with clear counseling that efficacy is lower 1
Systemic estrogen already prescribed but inadequate symptom control → Add low-dose vaginal estrogen or DHEA 3
Key Practical Points
- Creams have advantages for pessary users: They provide better coverage from introitus to apex and have an emollient effect that may help with pessary-related irritation 1
- Avoid petroleum jelly: Associated with increased bacterial vaginosis risk 1
- Olive oil is acceptable as a lubricant if needed 1
- Monitor for compatibility: Some vaginal preparations can damage pessary material, though this was not an issue with Trimo-San 2
Common Pitfalls
- Don't assume all patients need estrogen—assess for contraindications (active hormone-sensitive breast cancer is the main one) 1, 4
- Don't use systemic-dose vaginal estrogen (CEE 0.625-2.5 mg daily)—this causes LH/FSH suppression and defeats the purpose of local therapy 1
- Don't forget that vaginal estrogen may help prevent recurrent UTIs and overactive bladder symptoms, additional benefits for pessary users 1
- The boxed warnings on low-dose vaginal estrogen products regarding cardiovascular and breast cancer risks are not supported by evidence at these doses and are being challenged 1